Our Scientific Advisory Board, chaired by our scientific founder Jan Steyaert, has attracted world-leading experts
from the fields of three-dimensional structural analysis of membrane proteins, GPCR pharmacology and computational chemistry.
Jan is Scientific Director of the VIB-VUB Center for Structural Biology, Full Professor (“Gewoon Hoogleraar”) and Director of the Department of Structural Biology at the Faculty of Sciences and Bioengineering Sciences at the Vrije Universiteit Brussel (VUB; Brussels, Belgium).
He has pioneered the use of ConfoBodies® in structural biology, including the ConfoBody® known as ‘Nb80’, which was generated in Jan’s lab and subsequently used by Prof. Brian Kobilka and co-workers at Stanford University to achieve the first structure of an active-state GPCR conformation.
In addition to founding Confo Therapeutics, Jan was instrumental to the foundation of Ablynx (now part of Sanofi) and Biotalys, which deploy camelid single-domain antibodies for medical and agricultural use, respectively.
Radu is a program leader at the MRC Laboratory of Molecular Biology (Cambridge, UK). His research focuses on synaptic connectivity, and uses a combination of structural biology methods, including X-ray crystallography and cryo-electron microscopy. These are used to define in high resolution the architecture of neurotransmitter receptors and their supra-molecular assemblies, in order to provide fundamental mechanistic insights into the basic biology of neurotransmission.
Peter is a Professor of Pharmaceutical Chemistry, funded by the Heisenberg program of the German Research Foundation DFG, at Philipps-University (Marburg, Germany). He is an expert in fragment-based and structure-based ligand design for GPCRs and enzymes, focusing predominantly on computational approaches.
Graeme is a Professor of Molecular Pharmacology, Dean of Research at the College of Medical, Veterinary and Life Sciences, and Gardiner Professor of Biochemistry, University of Glasgow (Scotland). His research group centers on the function, structure and regulation of GPCRs and their interacting proteins, and has produced more than 500 peer-reviewed articles totaling more than 22,000 citations. In 2015 he co-founded Caldan Therapeutics, which discovers novel therapeutics for metabolic and inflammatory diseases.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.